Beta Bionics Reports Q3 2026 Revenue Growth Driven by Pharmacy Channel Expansion
Beta Bionics (BBNX) reported third-quarter net sales of $35.5 million, a 30% increase year-over-year driven by new patient starts and significant growth in the pharmacy benefit plan channel. While revenue grew, the company reported a net loss of $24.4 million due to increased investments in R&D and sales force expansion for its upcoming Mint patch pump and bihormonal programs. The company raised its full-year revenue guidance to a range of $124 million to $126 million. However, management cautioned that fourth-quarter revenue could face a deferral of up to $8.5 million as customers potentially delay purchases to wait for the commercial launch of the Mint patch pump in early 2027.
Tickers: $BBNX
Topics: Gross Margin Net Sales Growth Operating Expenses Pharmacy Benefit Plan Revenue Revenue Guidance